LLY

751.96

-3.18%↓

JNJ

155.56

-1.06%↓

UNH

385.73

-1.37%↓

ABBV

185.44

-1.29%↓

AZN

67.28

-4.02%↓

LLY

751.96

-3.18%↓

JNJ

155.56

-1.06%↓

UNH

385.73

-1.37%↓

ABBV

185.44

-1.29%↓

AZN

67.28

-4.02%↓

LLY

751.96

-3.18%↓

JNJ

155.56

-1.06%↓

UNH

385.73

-1.37%↓

ABBV

185.44

-1.29%↓

AZN

67.28

-4.02%↓

LLY

751.96

-3.18%↓

JNJ

155.56

-1.06%↓

UNH

385.73

-1.37%↓

ABBV

185.44

-1.29%↓

AZN

67.28

-4.02%↓

LLY

751.96

-3.18%↓

JNJ

155.56

-1.06%↓

UNH

385.73

-1.37%↓

ABBV

185.44

-1.29%↓

AZN

67.28

-4.02%↓

Search

Abbott Laboratories

Aperta

SettoreSettore sanitario

133.82 -0.01

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

132.39

Massimo

135.19

Metriche Chiave

By Trading Economics

Entrata

-7.9B

1.3B

Vendite

-616M

10B

P/E

Media del settore

17.221

54.379

EPS

1.09

Rendimento da dividendi

1.78

Margine di Profitto

12.792

Dipendenti

114,000

EBITDA

-1.2B

1.8B

Raccomandazioni

By TipRanks

Raccomandazioni

Fortemente da comprare

Previsioni per 12 mesi

+7.8% upside

Dividendi

By Dow Jones

Rendimento da dividendi

Media del settore

1.78%

2.55%

Prossima data del Dividendo

15 mag 2025

Prossima data del' Ex Dividendo

14 lug 2025

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

2.9B

231B

Apertura precedente

133.83

Chiusura precedente

133.82

Notizie sul Sentiment di mercato

By Acuity

33%

67%

116 / 382 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Neutral Evidence

Abbott Laboratories Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

16 apr 2025, 16:21 UTC

Utili

Abbott Labs Bracing for Tariffs as Profits Rise -- Update

16 apr 2025, 12:14 UTC

Utili

Abbott Labs 1Q Profit Jumps on Gains in Nutrition, Medical Devices

22 gen 2025, 19:03 UTC

Utili

Correction to Abbott Labs 4Q Sales Just Miss Estimates Article

22 gen 2025, 18:20 UTC

Utili

Abbott Labs 4Q Sales Just Miss Estimates; Shares Rise on 2025 Outlook -- Update

22 gen 2025, 12:45 UTC

Utili

Abbott Labs 4Q Sales Underwhelm Amid Diminished Demand for Covid-19 Related Sales

16 apr 2025, 15:09 UTC

Discorsi di Mercato

Abbott Says Tariffs Killed Chances of an Outlook Raise -- Market Talk

16 apr 2025, 14:17 UTC

Utili

Abbott Laboratories Stock Rises as First-Quarter Earnings Surpass Expectations -- Barrons.com

16 apr 2025, 11:34 UTC

Utili

Abbott Labs 1Q Gross Margin of 52.8 % of Sales; Adj Gross Margin of 57.1 % >ABT

16 apr 2025, 11:33 UTC

Utili

Abbott Labs Projects FY25 Adj Operating Margin to Be 23.5% to 24.0% of Sales >ABT

16 apr 2025, 11:32 UTC

Utili

Abbott Labs Backs FY25 Adj EPS $5.05-Adj EPS $5.25 >ABT

16 apr 2025, 11:32 UTC

Utili

Abbott Labs Sees 2Q Adj EPS $1.23-Adj EPS $1.27 >ABT

16 apr 2025, 11:31 UTC

Utili

Abbott Labs Projects FY25 Organic Sales Growth of 7.5% to 8.5% >ABT

16 apr 2025, 11:30 UTC

Utili

Abbott Reaffirms Full-Yr Guidance

16 apr 2025, 11:30 UTC

Utili

Abbott Labs 1Q Organic Sales Growth Up 6.9% >ABT

16 apr 2025, 11:30 UTC

Utili

Abbott Labs 1Q Sales $10.36B >ABT

16 apr 2025, 11:30 UTC

Utili

Abbott Labs 1Q Net $1.33B >ABT

16 apr 2025, 11:30 UTC

Utili

Abbott Labs 1Q EPS 76c >ABT

16 apr 2025, 11:30 UTC

Utili

Abbott Labs 1Q Adj EPS $1.09 >ABT

16 apr 2025, 09:57 UTC

Azioni calde

Stocks to Watch: Nvidia, AMD, Heineken, ASML -- WSJ

1 feb 2025, 18:14 UTC

Notizie principali

Musk's X Adds Nestlé, Colgate, Shell, Other Brands to Ad-Boycott Suit -- WSJ

22 gen 2025, 16:40 UTC

Notizie principali
Utili

Abbott Laboratories Stock Turns Positive. What to Know From Its Earnings. -- Barrons.com

22 gen 2025, 15:20 UTC

Utili

Abbott Laboratories Posts 'Middling' Quarter, But Diabetes Devices Shine -- IBD

22 gen 2025, 15:08 UTC

Utili

Abbott Laboratories Stock Falls After Earnings as Sales Miss Estimates -- Barrons.com

22 gen 2025, 13:51 UTC

Utili

Abbott Laboratories Slides On Light Fourth-Quarter Sales, In-Line Profit -- IBD

22 gen 2025, 13:39 UTC

Notizie principali
Utili

Abbott Laboratories Stock Falls After Earnings as Sales Miss Estimates -- Barrons.com

22 gen 2025, 12:02 UTC

Utili

Abbott Labs Sees 1Q Adj EPS $1.05-Adj EPS $1.09 >ABT

22 gen 2025, 12:01 UTC

Utili

Abbott Labs Sees 2025 Adj EPS $5.05-Adj EPS $5.25 >ABT

22 gen 2025, 12:01 UTC

Utili

Abbott Labs Sees 2025 Adjusted Operating Margin 23.5%-24% >ABT

22 gen 2025, 12:00 UTC

Utili

Abbott Labs Sees 2025 Organic Sales Growth 7.5%-8.5% >ABT

22 gen 2025, 12:00 UTC

Utili

Abbott Labs 4Q Net $9.23B >ABT

Confronto tra pari

Modifica del prezzo

Abbott Laboratories Previsione

Obiettivo di Prezzo

By TipRanks

7.8% in crescita

Previsioni per 12 mesi

Media 144.4 USD  7.8%

Alto 159 USD

Basso 127 USD

Basato su 21 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Abbott Laboratories - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

21 ratings

18

Acquista

3

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

132.89 / 136.8Supporto e resistenza

A breve termine

Neutral Evidence

A termine intermedio

Neutral Evidence

A lungo termine

Bullish Evidence

Sentiment

By Acuity

116 / 382 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Prove rialziste

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sopra la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also offers laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for laboratories. In addition, the company provides pediatric and adult nutritional products; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.